Company intelligence / Profile preview

C-Factor

Cambridge, Massachusetts, United Statesthetalentgames.com ↗

Ownership: Private
Development stage: Other

Overview

Developed foundational technologies in mRNA delivery and gene editing; enabling partners to advance iPSC-derived therapies into oncology, autoimmune disease, and rare disease indications. Recent multimillion-dollar contracts support development of novel treatments for hematologic and solid tumors using engineered lymphocytes from pluripotent stem cells. Patent portfolio successfully defended in US courts covering key methods for therapeutic gene editing.

Therapeutic areas: OncologyRare DiseasesImmunology
Modalities: mRNA-based drugsGene therapyCell therapyNucleic acid delivery technologiesInduced pluripotent stem cell derived therapy (iPSC)
Industry: Biotech

Partnerships

Eterna Therapeutics

Beyond the preview

Go deeper on C-Factor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-Factor.

Explore the full profile